In Situ Gene Therapy
- PMID: 33949931
- DOI: 10.2174/1566523221666210504103323
In Situ Gene Therapy
Abstract
Gene therapy is a technique that aims at the delivery of nucleic acids to cells, to obtain a therapeutic effect. In situ gene therapy consists of the administration of the gene product to a specific site. It possesses several advantages, such as the reduction in potential side effects, the need for a lower vector dose, and, as a consequence, reduced costs, compared to intravenous administration. Different vectors, administration routes and doses involving in situ gene transfer have been tested both in animal models and humans, with in situ gene therapy drugs already approved in the market. In this review, we present applications of in situ gene therapy for different diseases, ranging from monogenic to multifactorial diseases, focusing mainly on therapies designed for the intra-articular and intraocular compartments, as well as gene therapies for the central nervous system (CNS) and for tumors. Gene therapy finally seems to blossom as a viable therapeutic approach. The growth in the number of clinical protocols shown here is evident, and the positive outcomes observed in several clinical trials indicate that more products based on in situ gene therapy should reach the market in the next years.
Keywords: In situ gene therapy; gene therapy clinical trials.; intra-articular gene therapy; intracerebral gene therapy; intraocular gene therapy; intratumoral gene therapy.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The Challenge of Gene Therapy for Neurological Diseases: Strategies and Tools to Achieve Efficient Delivery to the Central Nervous System.Hum Gene Ther. 2021 Apr;32(7-8):349-374. doi: 10.1089/hum.2020.105. Epub 2021 Jan 26. Hum Gene Ther. 2021. PMID: 33167739
-
Viral vectors and delivery strategies for CNS gene therapy.Ther Deliv. 2010 Oct;1(4):517-34. doi: 10.4155/tde.10.50. Ther Deliv. 2010. PMID: 22833965 Free PMC article. Review.
-
Liposomal and viral vectors for gene therapy of the central nervous system.Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):453-65. doi: 10.2174/1568007054546144. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 16101560 Review.
-
Self-focusing therapeutic gene delivery with intelligent gene vector swarms: intra-swarm signalling through receptor transgene expression in targeted cells.Artif Intell Med. 2015 Jan;63(1):1-6. doi: 10.1016/j.artmed.2014.11.001. Epub 2014 Dec 17. Artif Intell Med. 2015. PMID: 25547266
-
Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system.Neurosurgery. 1997 Apr;40(4):805-12; discussion 812-3. doi: 10.1097/00006123-199704000-00028. Neurosurgery. 1997. PMID: 9092854 Review.
Cited by
-
Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome).Ther Clin Risk Manag. 2022 Dec 22;18:1143-1155. doi: 10.2147/TCRM.S351300. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36578769 Free PMC article. Review.
-
Unidirectional gene delivery electrospun fibrous membrane via charge repulsion for tendon repair.Bioact Mater. 2024 Mar 21;37:191-205. doi: 10.1016/j.bioactmat.2024.03.008. eCollection 2024 Jul. Bioact Mater. 2024. PMID: 38549775 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical